WorldStage– Substantial shareholder Clinoscope Services Limited has increased its equity stake in Neimeth International Pharmaceuticals Plc, acquiring 74,726,661 ordinary shares in a transaction valued at approximately ₦448.36 million.
According to a formal insider dealing notification filed with the Nigerian Exchange Limited (NGX) on November 13, 2026, the off-market or exchange-traded purchase took place in Lagos on November 10, 2026, at an average price of ₦6.00 per share.
Transaction Breakdown
Insider / Acquirer: Clinoscope Services Limited (Substantial Shareholder)
Issuer: Neimeth International Pharmaceuticals Plc (ISIN: NGNEIMETH001)
Transaction Type: Purchase of Ordinary Shares
Volume Acquired: 74,726,661 units
Execution Price: ₦6.00 per share
Total Transaction Value: ₦448,359,966.00
Transaction Date: November 10, 2026
Filing Date: November 13, 2026
Market & Investor Context
Insider share acquisitions of this scale are closely monitored by institutional and retail investors on the NGX as a potential signal of long-term confidence in a company’s valuation and growth trajectory. By committing nearly half a billion Naira at a uniform price of ₦6.00 per unit, Clinoscope Services Limited has reinforced its position as a key institutional backer of the Ikeja-based pharmaceutical manufacturer.
The disclosure, signed by Company Secretary Chinenye S. Adekanmbi, aligns with NGX post-listing requirements mandating transparency around significant share dealings by insiders and substantial shareholders.
About Clinoscope Services
Clinoscope Services Limited is a private limited liability company registered in Nigeria, most widely known in Nigerian financial markets as a substantial institutional shareholder in Neimeth International Pharmaceuticals Plc.
Corporate Overview
Registration & Status: Incorporated with the Corporate Affairs Commission (CAC) on March 29, 2021 (RC-1777131) as an active private company limited by shares.
Headquarters: Victoria Island, Lagos, Nigeria.
Primary Business Activity: Health education and medical consultancy services.
Ownership & Leadership: According to public registry filings, the sole person with significant control (100% shareholder and director) is Dr. Emmanuel Ifeanyi Ekwomadu, a medical practitioner.
Investment Activity on the Nigerian Exchange (NGX)
Clinoscope Services Limited actively accumulates equity in Neimeth International Pharmaceuticals Plc (ticker: NEIMETH), classifying it as an insider/substantial shareholder under NGX regulatory disclosure rules:
November 2026: Disclosed the purchase of an additional 74,726,661 ordinary shares at ₦6.00 per share (valued at roughly ₦448.36 million) in a transaction executed on November 10, 2026.
October 2026: Acquired 2.81 million additional shares in Neimeth. Earlier Acquisitions: Previously raised its stake through multi-million-share purchases, including a 40-million-share acquisition reported in late 2025/2026.




















































